The phylogeny of permanent prostate brachytherapy

Journal of Contemporary Brachytherapy

Volumn 5, Issue 2, 2013, Pages 89-92

  Aronowitz, Jesse N ^a   Rivard, Mark J ^b  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; History of medicine; Prostate cancer; Prostatic neoplasms

Indexed keywords

CESIUM; CESIUM ION; IODINE 125; PALLADIUM; PALLADIUM 103; RADIUM 226; RADON 222; TITANIUM;

BRACHYTHERAPY; CLINICAL PRACTICE; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PHYLOGENY; PRESCRIPTION; PROSTATE CANCER; PROSTATE SURGERY; RADIATION DOSE; RADIATION INJURY; RADIOISOTOPE THERAPY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 84882391783     PISSN: 1689832X     EISSN: None     Source Type: Journal    
DOI: 10.5114/jcb.2013.35562     Document Type: Review

References (46)

1. Potters L, Morgenstern C, Calugaru E et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562-1566. (Pubitemid 40524771)
2. Sylvester J, Grimm P, Wong J et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following 125I prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2010;81:376-381.
3. Crook J, Borg J, Evans A et al. 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1, 100 patients. Int J Radiat Oncol Biol Phys 2011;80:1323-1329.
4. Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012;11:6-19.
5. Minet H. Applications du radium aux tumeurs vesicales, a l'hy - pertrophie et au cancer de la prostate, etc. Proc Verb Mem Assoc Franc Urol 1909;13:629-646.
6. Desnos E. Action du radium sur la prostate hypertrophiée. Proc Verb Mem Assoc Franc Urol 1909;13:646-656.
7. Barringer BS. Radium in the treatment of carcinoma of the bladder and prostate: Review of one year's work. JAMA 1916;68:1227-1230.
8. Failla G. Physical considerations relative to the application of radium. In: Janeway HH (ed.). Radium therapy in cancer at the Memorial Hospital, New York. Paul B. Hoeber, New York 1917, pp. 23-25.
9. Duane W. Methods of preparing and using radioactive substances in the treatment of malignant disease, and of estimating suitable dosages. Boston Med Surg J 1917;177:787-799.
10. Aronowitz JN. Buried emanation: the development of seeds for permanent implantation. Brachytherapy 2002;1:167-178. (Pubitemid 37356904)
11. Failla G. Radium technique at the Memorial Hospital, New York. Arch Radiol Electrother 1920;25:3-19.
12. Ward W, Smith A J D. Recent advances in radium. Blakiston, Philadelphia 1933.
13. Lubenau JO. A century's challenge: historical overview of radia tion sources in the U. S. A. IAEA Bull 1999;41:49-54.
14. Aronowitz JN. Don Lawrence and the "k-capture" revolution. Brachytherapy 2010;9:373-381.
15. Rivard MJ. Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 125I brachytherapy sources. Med Phys 2009;36:486-491.
16. Kennedy RM, Davis SD, Micka JA et al. Experimental and Monte Carlo determination of TG-43 dosimetric parameters for the model 9011 Thin SEEDTM brachytherapy source. Med Phys 2010;37:1681-1688.
17. ™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer; available at: http://clinicaltrials.gov/ct2/show/study/NCT01379742, last accessed April 14, 2013.
18. Nag S, Beyer D, Friedland J et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799. (Pubitemid 29284127)
19. Beyer D, Nath R, Butler W et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:273-275. (Pubitemid 30236365)
20. Rivard MJ, Butler WM, Devlin PM et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 2007;6:34-37. (Pubitemid 46187324)
21. Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linearquadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-87.
22. Dale RG. Comparison of the radiobiological effects of Cs-131 im plants with those associated with I-125 and Pd-103 im - plants. Iso Ray Medical, Richland 2004.
23. Paterson R, Parker HM. A dosage system for interstitial radium therapy. Br J Radiol 1938;11:252-266.
24. Quimby EH, Castro V. The calculation of dosage in interstitial radium therapy. Am J Roentgenol Radium Ther Nucl Med 1953;70:739-759.
25. Quimby EH. Dose calculation in radium therapy. Am J Roentg - enol Radium Ther 1947;57:622-627.
26. Henschke UK. Interstitial implantation of unresectable lung cancer. In: Rajewsky B (ed.). IXth International congress of radiology. Georg Thieme Verlag, Stuttgart 1960, pp. 580-586.
27. Kim JH, Hilaris B. Iodine 125 source in interstitial therapy. Am J Roentgenol 1975;123:163-169.
28. Henschke UK, Cevc P. Dimension averaging a simple method for dosimetry of interstitial implants. Rad Biol Ther 1968;9:282-298.
29. Anderson LL. Spacing nomograph for interstitial implants of 125I seeds. Med Phys 1976;3:48-51.
30. Whitmore WF, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol 1972;108:918-920.
31. Holm HH, Juul N, Pedersen JF et al. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-286. (Pubitemid 13037600)
32. Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hypertherm Oncol 1987;3:131-139.
33. Williamson JF, Coursey BM, De Werd LA et al. Guidance to users of Nycomed Amersham and North American Scienti fic, Inc. I-125 Interstitial Sources: Dosimetry and calibration changes: Recommendation of the American Association of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry. Med Phys 1999;26:570-573. (Pubitemid 29186277)
34. Seltzer SM, Lamperti PJ, Loevinger R et al. New national airkermastrength standards for 125I and 103Pd brachytherapy seeds. J Res Natl Inst Stand Technol 2003;108:337-358.
35. Stone NN, Stock RG, Cesaretti JA et al. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010;76:355-360.
36. Alex A, Galloway, M, Landreneau R et al. Intraoperative 125I brachytherapy for high-risk Stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 1999;44:1057-1063. (Pubitemid 29342907)
37. Yang Y, Rivard MJ. Evaluation of brachytherapy lung implant dose distributions from photon-emitting sources due to tissue heterogeneities. Med Phys 2011;38:5857-5862.
38. Stone NN, Potters L, Davis BJ et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 2007;69:1472-1477. (Pubitemid 350116395)
39. Morris WJ, Keyes M, Palma D et al. Evaluation of dosimetric parameters and disease response after 125iodine transperineal brachytherapy for low-and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:1432-1438.
40. Iversen P, Baak M, Juul N et al. Ultrasonically guided iodine-125 seed implantation with external radiation in management of localized prostatic carcinoma. Urology 1989;34:181-186. (Pubitemid 19255941)
41. Tomaszewski JJ, Smaldone MC, Makaroun S et al. Cesium 131 versus iodine 125 implants for prostate cancer: evaluation of early PSA response. Can J Urol 2010;17:5360-5364.
42. Kollmeier MA, Pei X, Algur E et al. Comparison of the impact of isotope (125I vs. 103Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer. Brachytherapy 2012;11:271-276.
43. Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of iodine-125 and palladium-103 for the treatment of early stage prostate cancer. Atlas Urol Clin NA 1994;2:113-125.
44. Grimm PD, Blasko JC, Sylvester JE et al. Technical improvement in permanent seed implantation: a two-stage brachytherapy system. Description and comparison with current technique. Brachytherapy 2004;3:34-40. (Pubitemid 38521159)
45. Nath R, Bice WS, Butler WM et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys 2009;36:5310-5322.
46. Rivard MJ, Venselaar J L M, Beaulieu L. The evolution of bra - chytherapy treatment planning. Med Phys 2009;36:2136-2153.